{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T17:51:18Z","timestamp":1680285078801},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Dermatol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12895-016-0042-5","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:08:41Z","timestamp":1464221321000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C"],"prefix":"10.1186","volume":"16","author":[{"given":"Eva","family":"Lemmenmeier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,26]]},"reference":[{"issue":"6","key":"42_CR1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","volume":"312","author":"A Kohli","year":"2014","unstructured":"Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631\u201340.","journal-title":"JAMA"},{"issue":"1","key":"42_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622314551934","volume":"6","author":"KJ Cortez","year":"2015","unstructured":"Cortez KJ, Kottilil S. Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 2015;6(1):4\u201314.","journal-title":"Ther Adv Chronic Dis"},{"issue":"10","key":"42_CR3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1155\/2009\/651952","volume":"23","author":"N Mistry","year":"2009","unstructured":"Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23(10):677\u201383.","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"42_CR4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000353160","volume":"228","author":"I Patrk","year":"2014","unstructured":"Patrk I, Morovi\u0107 M, Markulin A, Patrk J. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin. Dermatol Basel Switz. 2014;228(1):42\u20136.","journal-title":"Dermatol Basel Switz"},{"issue":"1","key":"42_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199\u2013236.","journal-title":"J Hepatol"},{"issue":"6","key":"42_CR6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/cid\/cit799","volume":"58","author":"DS Fierer","year":"2014","unstructured":"Fierer DS, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58(6):873\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"42_CR7","first-page":"841","volume":"89","author":"A Hawilo","year":"2011","unstructured":"Hawilo A, Zaraa I, Benmously R, Mebazaa A, El Euch D, Mokni M, et al. Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases. Tunis M\u00e9dicale. 2011;89(11):841\u20137.","journal-title":"Tunis M\u00e9dicale"},{"issue":"1","key":"42_CR8","first-page":"48","volume":"4","author":"AH Sharifi","year":"2012","unstructured":"Sharifi AH, Fakharzadeh E, Zamini H, Haj-Sheykholeslami A, Jabbari H. Exacerbation of Skin Lesions in a 50\u00a0year old Man with Psoriasis during Treatment by Pegylated Interferon. Middle East J Dig Dis. 2012;4(1):48\u201350.","journal-title":"Middle East J Dig Dis"},{"issue":"12","key":"42_CR9","first-page":"760","volume":"11","author":"A Horev","year":"2009","unstructured":"Horev A, Halevy S. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C. Isr Med Assoc J IMAJ. 2009;11(12):760\u20131.","journal-title":"Isr Med Assoc J IMAJ"},{"issue":"17-18","key":"42_CR10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00508-013-0408-1","volume":"125","author":"MS Dag","year":"2013","unstructured":"Dag MS, Ozt\u00fcrk ZA, Y\u0131lmaz N, Cam H, Kaday\u0131f\u00e7\u0131 A. Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature. Wien Klin Wochenschr. 2013;125(17-18):537\u201340.","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"42_CR11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1468-3083.2012.04582.x","volume":"27","author":"M Afshar","year":"2013","unstructured":"Afshar M, Martinez AD, Gallo RL, Hata TR. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol JEADV. 2013;27(6):771\u20138.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"3","key":"42_CR12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jcv.2014.04.012","volume":"60","author":"Z Li","year":"2014","unstructured":"Li Z, Zhang Y, An J, Feng Y, Deng H, Xiao S, et al. Predictive factors for adverse dermatological events during pegylated\/interferon alpha and ribavirin treatment for hepatitis C. J Clin Virol. 2014;60(3):190\u20135.","journal-title":"J Clin Virol"},{"issue":"4","key":"42_CR13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00365548.2012.720026","volume":"45","author":"F Bartalesi","year":"2013","unstructured":"Bartalesi F, Salomoni E, Cavallo A, Corti G, Pimpinelli N, Bartoloni A, et al. Chronic hepatitis C virus hepatitis and psoriasis: no longer a contraindication to interferon use in the era of biological agents? Scand J Infect Dis. 2013;45(4):320\u20133.","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"42_CR14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2230.2009.03476.x","volume":"35","author":"SE Behnam","year":"2010","unstructured":"Behnam SE, Hindiyeh R, Fife DJ, Jeffes 3rd EW, Wu JJ. Etarnercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol. 2010;35(4):397\u20138.","journal-title":"Clin Exp Dermatol"}],"container-title":["BMC Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12895-016-0042-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:03:31Z","timestamp":1498302211000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcdermatol.biomedcentral.com\/articles\/10.1186\/s12895-016-0042-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1186\/s12895-016-0042-5","relation":{},"ISSN":["1471-5945"],"issn-type":[{"value":"1471-5945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]},"article-number":"5"}}